Meet the Team
behind Tubulis

Jonas Helma-Smets, PhD, serves as Chief Scientific Officer at Tubulis.

Jonas brings more than 10 years experience in biotechnology and antibody engineering to Tubulis and secured several prestigious start-up awards for the company. Prior to co-founding Tubulis, Jonas was a Group Leader at the Ludwig-Maximilians University (LMU) in Munich. He also co-founded ChromoTek GmbH, a company focused on developing nanobody derivatives for proteome analysis and cell-based diagnostics.

Jonas studied biology and obtained his PhD in Cell and Molecular Biology at the LMU in Munich.

Ingo Lehrke, PhD, serves as Chief Business Officer at Tubulis.

Ingo brings over 20 years experience in the pharmaceutical industry to Tubulis and a passion for strategic business development. He also serves as Chief Executive Officer at Algiax Pharmaceuticals, a company developing treatments for neuropathic pain. Prior, he held the position of Managing Director at the drug delivery company tesa Labtec GmbH.

Ingo studied pharmaceutics at the University of Münster and obtained his PhD at the University of Heidelberg. He also studied business administration, specialising in marketing and finance.

Günter Fingerle-Rowson, PhD, MD, serves as Chief Medical Officer at Tubulis.

Günter brings more than 12 years of academic, biotechnology and pharmaceutical industry experience to Tubulis. He worked in Global Clinical Development at MorphoSys and F. Hoffmann-La Roche as well as in Medical Affairs at Janssen-Cilag. Günter has gained a lot of experience throughout of all phases of clinical development and successfully brought three novel drugs to cancer patients.

Günter obtained his MD from the Ludwig-Maximilians University (LMU) in Munich and a MD PhD in Molecular Medicine from New York University and is board-certified in hematology / medical oncology and in internal medicine.

Björn Hock is a seasoned expert in protein therapeutics and the ADC space and serves as the Chief Development Officer of Tubulis on a consultant basis.

Most recently, he served as interim CEO at Aerium Therapeutics (formerly SwissThera SA). From 2017 until 2021, he was the Vice President of Biologics, Technologies and Development at Ferring Pharmaceuticals. Prior, he worked in various positions at Merck for more than ten years, including his position as the Senior Director and Global Head of ADC and Targeted Therapeutics, where he oversaw the development of protein therapeutics from concept to lead stage.

Dr. Hock obtained his PhD in Biochemistry at the Chemotherapeutisches Forschungsinstitut Georg Speyer-Haus.

Mary Ann Lumiqued serves as Vice President Program Management at Tubulis.

Mary Ann brings more than 20 years of experience in the management of drug development and commercialization projects as well as in the development and execution of medical affairs strategies to Tubulis. Previously, she worked at MorphoSys as Program Leader Proprietary Development and, most recently, as Head of Global Medical Affairs Project Strategy and Operations. Before that, she held leading positions at private and public life sciences companies, including Ipsen, where she successfully directed and implemented lifecycle product development and brand strategy plans.

Mary Ann has a Bachelor’s degree in Animal Physiology and Neuroscience as well as a Professional Award in Biotechnology Management from the University of California, San Diego and Santa Cruz.

Armin Weidmann, PhD, serves as Vice President Quality at Tubulis.

Armin brings 20 years of expertise in the biotech industry to Tubulis with extensive leadership experience in the areas of GxP quality management, compliance management and corporate internal audit functions. Previously, he worked in several positions at MorphoSys AG, with increasing responsibilities including VP Head of Global QA & Internal Audit and VP Head of Global Compliance & QA, where he led development and commercial quality management and compliance programs in Germany and the US.

Armin studied biochemistry at the University of Bayreuth, Germany, and obtained his PhD in Virology & Immunology at the Julius-Maximilians University of Würzburg, Germany. After two years of post-doctoral studies in Germany and USA he joined the biotech industry.

Olivier Marcq, PhD, serves as Vice President CMC at Tubulis.

Olivier is an expert in bioconjugation therapeutics with more than 15 years of leadership expertise in the pharmaceutical industry encompassing CMC operation and strategy, GMP manufacturing as well as R&D, early and late phase development of biologics, particularly ADCs and conjugate vaccines. Previously, he was working in several positions at Vaxcyte including Senior Director, where he led programs and well as process development and manufacturing activities for multivalent bioconjugate vaccines. Olivier is also the founder and Principal of Omnium Bioconsulting, that provides bioconjugates process development and CMC strategy counseling. His prior experiences also comprise positions at Astellas Pharma, Pfizer and Wyeth, where he led team and projects for the development and manufacturing of ADCs and other bioconjugate therapeutics.

Olivier obtained his PhD in Chemistry at the Université de Bourgogne, France.